Drug intelligence / Profile preview

bendamustine + capecitabine

Development stage: Unknown
Lead developer: Jenapharm
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination chemotherapy regimen consisting of bendamustine and capecitabine. Bendamustine is a cytotoxic alkylating agent while capecitabine is a fluoropyrimidine carbamate antimetabolite that functions as a prodrug of 5-fluorouracil (5-FU). This combination has shown promising efficacy and moderate toxicity in clinical trials for pretreated patients with HER2-negative advanced breast cancer. In the AGMT MBC-6 phase II trial, the combination demonstrated an overall response rate of 53% and a clinical benefit rate of 60%, with a preliminary median progression-free survival of 8.9 months.

Targets

DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on bendamustine + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bendamustine + capecitabine.

Explore the full profile